Moreover, for non-small cell lung cancer (NSCLC) and urothelial carcinoma (UC), patients treated with PD-1/PD-L1 inhibitors exclusively exhibited a significant higher risk of all-grade ALT elevation incidence (NSCLC: RR, 1.92; 95% CI, 1.23-3.02; <i>p</i> = 0.004; UC: RR, 3.36; 95% CI, 1.12-10.06, <i>p</i> = 0.03) and all-grade AST elevation incidence (NSCLC: RR, 2.37; 95% CI, 1.45-3.87, <i>p</i> = 0.0005; UC: RR, 4.47; 95% CI, 1.30-15.38, <i>p =</i> 0.02) than chemotherapy. This evidence concerns the gene GPT and non-small cell lung carcinoma.